From: ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes
Systemic, n° of patients (%)
3 (11.5%)
Local, n° of patients (%)
6 (23.1%)
Pain
Bladder spasm
Dysuria
5 (15.4%)
Hematuria
1 (3.8%)
Difficult catheter insertion
Frequency/urgency
Nocturia
2 (7.7%)